opt shareholders deserve a conference call, page-16

Yes, there’s probably a review happening right now. If I were the DFA partner or Regal, it would be nuts to zero out the investment before commissioning a full independent analysis.

I’m 100% certain they had a team of PhD types review the Phase 2b data thoroughly before committing, thus I highly doubt they’d just accept a simple “nah, it flopped” before writing off their combined US$300M+.

The inexplicable improvement in the control arm; from 7–9 letters to 13–14; and the drop in treatment arm results from 16 down to13–14 letters suggest there’s been a complete loss of separation between control and treatment arms, not just at a few trial sites but holistically, yet this is the most foundation aspect for any science and clinical trial delivery team.

Anyway strongly believe that OPT should have investor update meeting, I know it would be ugly and I know they dont have all the answers, but as a holder being ghosted is completely unaceptable.